The-Inflection-Point-For-Nucleic-Acid-Drugs-is-a-Targeting-Problem

The CEO of Dyne Therapeutics presents a 40-year history of oligonucleotide therapeutics at the 2026 Danaher Summit, arguing that targeted delivery — not chemistry — is now the critical remaining bottleneck. He introduces Dyne's FORCE platform (a Fab fragment conjugated to interchangeable oligonucleotide payloads via TFR1 targeting) and presents clinical data showing unprecedented functional improvement from baseline in DMD patients across all seven measured endpoints. The talk closes with the next frontier: scaling the FORCE platform across all DMD exons and solving the economic challenge of manufacturing individualized genetic medicines for diminishing patient populations.

Key Takeaways

Delivery is the final bottleneck for nucleic acid medicines: chemistry challenges were solved over 40 years and targeted delivery will drive the next wave of approved drugs beyond liver targets.
Dyne Therapeutics' FORCE platform (Fab-TFR1 conjugate) achieves 30-50x higher muscle delivery versus naked PMO in primates, and crosses the blood-brain barrier IV without intrathecal injection.
Dyne's DMD exon 51 trial showed functional improvement from baseline across all 7 measured endpoints at 6 and 24 months — described as unprecedented — with dystrophin levels reaching ~10% unadjusted (~20% muscle content-adjusted) at 12-24 months versus 0.4-0.5% baseline.
FORCE-delivered siRNA targeting MAPT achieved 75% tau mRNA knockdown across the whole brain of monkeys via IV, versus 50% CSF tau knockdown by Biogen's BIB080 given intrathecally, suggesting a CNS delivery advantage for systemic TFR1-targeting platforms.
Avidity Biosciences' acquisition by Novartis for $12 billion in 2026 validates the commercial potential of antibody-oligonucleotide conjugate platforms for neuromuscular diseases.
Over 340 nucleic acid drugs are in active clinical trials as of 2026, predominantly targeting the liver via GalNAc conjugates; delivering beyond the liver (muscle, CNS, heart) is the next growth frontier.
Expanding DMD exon skipping to cover ~80% of patients requires addressing exons with patient populations as small as n=1, presenting unsolved manufacturing and economic challenges for the genetic medicine field.